BI 1569912 / Boehringer Ingelheim - LARVOL DELTA

A Study to Test Different Doses of BI 1569912 in People With Depression (clinicaltrials.gov) - P2 | N=224 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine (clinicaltrials.gov) - P2 | N=84 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study to Test Different Doses of BI 1569912 in People With Depression (clinicaltrials.gov) - P2 | N=224 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine (clinicaltrials.gov) - P2 | N=84 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting | N=204 ➔ 84

Enrollment change • Enrollment closed • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study to Test Different Doses of BI 1569912 in People With Depression (clinicaltrials.gov) - P2 | N=222 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Oct 2025 ➔ May 2025 | Trial primary completion date: Oct 2025 ➔ May 2025

Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study in Healthy Men to Test How BI 1569912 is Processed in the Body (clinicaltrials.gov) - P1 | N=8 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion

A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine (clinicaltrials.gov) - P2 | N=204 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Oct 2025 ➔ Feb 2025 | Trial primary completion date: Aug 2025 ➔ Feb 2025

Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study in Healthy Men to Test How BI 1569912 is Processed in the Body (clinicaltrials.gov) - P1 | N=8 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Test Different Doses of BI 1569912 in People With Depression (clinicaltrials.gov) - P2 | N=222 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion

A Study in Healthy Men to Test How BI 1569912 is Processed in the Body (clinicaltrials.gov) - P1 | N=8 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Test Different Doses of BI 1569912 in People With Depression (clinicaltrials.gov) - P2 | N=222 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P2 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study in Healthy Men to Test How BI 1569912 is Processed in the Body (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P1 trial

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated (clinicaltrials.gov) - P1 | N=76 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion

A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated (clinicaltrials.gov) - P1 | N=76 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open

A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P1 trial

A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine (clinicaltrials.gov) - P2 | N=204 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine (clinicaltrials.gov) - P2 | N=204 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P2 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated (clinicaltrials.gov) - P1 | N=84 | Recruiting | Sponsor: Boehringer Ingelheim | N=60 ➔ 84 | Trial completion date: Mar 2024 ➔ Jun 2024 | Trial primary completion date: Mar 2024 ➔ Jun 2024

Enrollment change • Trial completion date • Trial primary completion date

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication (clinicaltrials.gov) - P1 | N=59 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication (clinicaltrials.gov) - P1 | N=59 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated (clinicaltrials.gov) - P1 | N=56 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Sep 2023 ➔ Dec 2023 | Trial primary completion date: Sep 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date